drugset
drugset / Trial / NCT00909766

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

NCT00909766 ↗

Phase 1/2 Completed 113 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and effect on body weight and other obesity-related factors of different doses of BMS-830216, compared to placebo. The study will also determine the amount of BMS-830216 in the blood.

Timeline

Start
2009-08
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator BMS-830216 Small molecule 30 mg Oral
Comparator BMS-830216 Small molecule 100 mg Oral
Comparator BMS-830216 Small molecule 300 mg Oral
Comparator BMS-830216 Small molecule 600 mg Oral
Comparator BMS-830216 Small molecule 1200 mg Oral

Indications

obesity disorder